Bind Therapeutics, Inc. IPO Research Information

Bind Therapeutics, Inc. IPO Advisory

Share this IPO Profile:

Smart Search

For IPO Boutique's "scale of 1 to 5" BUY rating on Bind Therapeutics, Inc., and our comprehensive analysis, click "Buy Market Research".

Company	Symbol	Price Range	Issue Price	Open	Shares	Trade Date
Bind Therapeutics, Inc.	BIND - NASDAQ	$14.00-$16.00	$15.00	$15.00	4.7 million	9/20/2013
Underwriter(s): Credit Suisse, Cowen & Co.
Co-Manager(s): Stifel, JMP Securities
Industry: Health Care
Filing(s): Filed 2013-08-12

Bind Therapeutics, Inc. Quote & Chart - Click for current quote - BIND

About Bind Therapeutics, Inc. (adapted from Bind Therapeutics, Inc. prospectus):
They are a clinical-stage nanomedicine platform company developing Accurins, their novel targeted and programmable therapeutics.

This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.

IPO Boutique aggregates information on public companies and private companies, such as "BIND" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.